Document is current
Any future updates will be listed below
-
Authors
Bock, Christoph https://orcid.org/0000-0001-6091-3088
Datlinger, Paul
Chardon, Florence
Coelho, Matthew A. https://orcid.org/0000-0003-3737-2468
Dong, Matthew B.
Lawson, Keith A.
Lu, Tian
Maroc, Laetitia
Norman, Thomas M.
Song, Bicna
Stanley, Geoff
Chen, Sidi https://orcid.org/0000-0002-3819-5005
Garnett, Mathew
Li, Wei https://orcid.org/0000-0002-2163-7903
Moffat, Jason https://orcid.org/0000-0002-5663-8586
Qi, Lei S.
Shapiro, Rebecca S.
Shendure, Jay
Weissman, Jonathan S.
Zhuang, Xiaowei
- License Information
-
More Information
Article History
Accepted: 21 December 2021
First Online: 10 February 2022
Competing interests
: C.B. is a co-founder and scientific advisor of Aelian Biotechnology and Neurolentech. S.C. is a co-founder of EvolveImmune Therapeutics and Cellinfinity Bio. M.G. has performed consultancy for Sanofi, receives research funding from AstraZeneca and GlaxoSmithKline, and is a co-founder of Mosaic Therapeutics. J.M. is a shareholder of Northern Biologics and Pionyr Immunotherapeutics, and a scientific advisor and shareholder of Century Therapeutics and Aelian Biotechnology. L.S.Q. is a co-founder and scientific advisor of Epicrispr Biotechnologies and Refuge Biotechnologies. J.S. is a scientific advisor of Maze Therapeutics, Camp4 Therapeutics, Cajal Biosciences, Adaptive Biotechnologies and Guardant Health, and a co-founder of Scale Bio and Phase Genomics. J.S.W. consults for and holds equity in KSQ Therapeutics, Maze Therapeutics and Tenaya Therapeutics, is a venture partner at 5AM Ventures and is a member of the Amgen Scientific Advisory Board. X.Z. is a co-founder and consultant of Vizgen. The other authors declare no competing interests.
